Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14242632 | 0.93 | MEN1 (0.43) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL2887782 | 0.90 | USP2 (0.49) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL25303284 | 0.89 | MEN1 (0.43) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL22983614 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CYP11B2MEN1ALDH1A1 | |
| SCHEMBL21458064 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2USP30RORC | |
| SCHEMBL28604412 | 0.81 | VNN1 (0.46) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL28587335 | 0.81 | VNN1 (0.46) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL13993957 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL2377946 | 0.81 | VNN1 (0.46) | USP2SMN1; SMN2CTSKCYP11B2MEN1 | |
| SCHEMBL475749 | 0.80 | USP2 (0.47) | USP2SMN1; SMN2CYP11B2USP30RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | USP2 1770/4885SMN1; SMN2 4812/4885CTSK 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.